10 Best Small Cap Stocks to Buy Now - 10 of 10 Slide 10Back to 9Next Slideshow Back to 9Next Slideshow Quince Therapeutics (NASDAQ:QNCX)Consensus Rating BuyRating Score 3.3Ratings Breakdown 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.Consensus Price Target $9.50 (578.6% Upside)About Quince TherapeuticsQuince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. More Recent Analyst RatingsDateBrokerageActionRatingPrice TargetDetails2/5/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$12.00 ➝ $12.001/2/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$12.00 ➝ $12.0012/18/2024Brookline Capital ManagementInitiated CoverageBuy$9.0011/7/2024Maxim GroupInitiated CoverageBuy$6.0010/29/2024RODMAN&RENSHAWUpgradeStrong-Buy10/29/2024Rodman & RenshawInitiated CoverageBuy$11.0010/22/2024EF Hutton Acquisition Co. IUpgradeStrong-BuyMore Investing Slideshows:7 High-Growth Stocks Under $107 Dividend Stocks That Show Why Cash Is King7 Stocks to Buy as Esports Goes Mainstream7 Silver Stocks Set to Sizzle on Higher DemandProfit Without Panic: 7 ETFs to Diversify Your Portfolio7 Flying Car Stocks to Buy Before the Sector Really Takes Off7 Uranium Stocks That Can Fuel a Growth Portfolio7 Growth Stocks Positioned for Further Growth7 Defensive Stocks to Shield Your Portfolio from Inflation7 Stocks Under $20 That Could Double Your MoneySlide 10Back to 9Next Slideshow More From MarketBeatMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored7 Stocks Set to Rally From Trump TariffsA Donald Trump presidency is likely to bring with it significant tariff enforcement. The president-elect campa...MarketBeatIgnore Fox Business’s “man who calls it all” at your perilThis is the biggest AI investment story you’ve never been told… and people who invest before March 19 could st...The Oxford Club | Sponsored7 AI Stocks Under $50 Set to Lead the Second Wave of Innovation If artificial intelligence is going to change every aspect of our lives, why do so many investors dismiss it...MarketBeatThis Crypto Is Set to Explode in FebruaryA little-known IRS loophole has been gaining serious attention... If you have a retirement account, you can...Premier Gold Co | Sponsored7 Sensational Small-Cap Stocks Set for Big GainsThe Russell 2000 Index is up more than 40% in the last 12 months. This is an index that tracks the performance...MarketBeat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Slide 10Back to 9Next Slideshow Back to 9Next Slideshow Quince Therapeutics (NASDAQ:QNCX)Consensus Rating BuyRating Score 3.3Ratings Breakdown 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.Consensus Price Target $9.50 (578.6% Upside)About Quince TherapeuticsQuince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. More Recent Analyst RatingsDateBrokerageActionRatingPrice TargetDetails2/5/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$12.00 ➝ $12.001/2/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$12.00 ➝ $12.0012/18/2024Brookline Capital ManagementInitiated CoverageBuy$9.0011/7/2024Maxim GroupInitiated CoverageBuy$6.0010/29/2024RODMAN&RENSHAWUpgradeStrong-Buy10/29/2024Rodman & RenshawInitiated CoverageBuy$11.0010/22/2024EF Hutton Acquisition Co. IUpgradeStrong-BuyMore Investing Slideshows:7 High-Growth Stocks Under $107 Dividend Stocks That Show Why Cash Is King7 Stocks to Buy as Esports Goes Mainstream7 Silver Stocks Set to Sizzle on Higher DemandProfit Without Panic: 7 ETFs to Diversify Your Portfolio7 Flying Car Stocks to Buy Before the Sector Really Takes Off7 Uranium Stocks That Can Fuel a Growth Portfolio7 Growth Stocks Positioned for Further Growth7 Defensive Stocks to Shield Your Portfolio from Inflation7 Stocks Under $20 That Could Double Your MoneySlide 10Back to 9Next Slideshow More From MarketBeatMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored7 Stocks Set to Rally From Trump TariffsA Donald Trump presidency is likely to bring with it significant tariff enforcement. The president-elect campa...MarketBeatIgnore Fox Business’s “man who calls it all” at your perilThis is the biggest AI investment story you’ve never been told… and people who invest before March 19 could st...The Oxford Club | Sponsored7 AI Stocks Under $50 Set to Lead the Second Wave of Innovation If artificial intelligence is going to change every aspect of our lives, why do so many investors dismiss it...MarketBeatThis Crypto Is Set to Explode in FebruaryA little-known IRS loophole has been gaining serious attention... If you have a retirement account, you can...Premier Gold Co | Sponsored7 Sensational Small-Cap Stocks Set for Big GainsThe Russell 2000 Index is up more than 40% in the last 12 months. This is an index that tracks the performance...MarketBeat
